JP2020506962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506962A5 JP2020506962A5 JP2019560066A JP2019560066A JP2020506962A5 JP 2020506962 A5 JP2020506962 A5 JP 2020506962A5 JP 2019560066 A JP2019560066 A JP 2019560066A JP 2019560066 A JP2019560066 A JP 2019560066A JP 2020506962 A5 JP2020506962 A5 JP 2020506962A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- hla
- antibody
- neoantigen
- cancer cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims 74
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims 74
- 210000004027 cell Anatomy 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- ICTPRLMOGAKCOZ-HWVMREAWSA-N NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O)C(C)C)CC1=CC=C(O)C=C1 Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O)C(C)C)CC1=CC=C(O)C=C1 ICTPRLMOGAKCOZ-HWVMREAWSA-N 0.000 claims 4
- 102000028650 human MAGE-A1 protein (278-286) Human genes 0.000 claims 4
- 108091005020 human MAGE-A1 protein (278-286) Proteins 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 claims 2
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims 2
- 108010024164 HLA-G Antigens Proteins 0.000 claims 2
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 claims 2
- 101000993059 Homo sapiens Hereditary hemochromatosis protein Proteins 0.000 claims 2
- 101000866971 Homo sapiens Putative HLA class I histocompatibility antigen, alpha chain H Proteins 0.000 claims 2
- 102100031498 Putative HLA class I histocompatibility antigen, alpha chain H Human genes 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 238000004581 coalescence Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023102868A JP2023134503A (ja) | 2017-01-24 | 2023-06-22 | 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762449954P | 2017-01-24 | 2017-01-24 | |
| US62/449,954 | 2017-01-24 | ||
| US201762460585P | 2017-02-17 | 2017-02-17 | |
| US62/460,585 | 2017-02-17 | ||
| PCT/US2018/015086 WO2018140525A1 (en) | 2017-01-24 | 2018-01-24 | Methods and compositions for targeting a complex comprising non-classical hla-i and neoantigen in cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023102868A Division JP2023134503A (ja) | 2017-01-24 | 2023-06-22 | 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506962A JP2020506962A (ja) | 2020-03-05 |
| JP2020506962A5 true JP2020506962A5 (cg-RX-API-DMAC7.html) | 2021-03-04 |
| JP7303750B2 JP7303750B2 (ja) | 2023-07-05 |
Family
ID=62979691
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560066A Active JP7303750B2 (ja) | 2017-01-24 | 2018-01-24 | 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物 |
| JP2023102868A Pending JP2023134503A (ja) | 2017-01-24 | 2023-06-22 | 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023102868A Pending JP2023134503A (ja) | 2017-01-24 | 2023-06-22 | 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190071502A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3573997A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7303750B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110809580A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018140525A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| EP4461371A3 (en) | 2014-12-23 | 2025-02-26 | immatics biotechnologies GmbH | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers |
| EP3539552A1 (en) * | 2018-03-16 | 2019-09-18 | Deutsches Rheuma-Forschungszentrum Berlin | Activation and expansion of nkg2c+ nk cells |
| CA3107001A1 (en) * | 2018-07-23 | 2020-01-30 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use |
| KR20210089193A (ko) * | 2018-11-01 | 2021-07-15 | 버클리 라잇츠, 인크. | 미세유체 디바이스에서 생물학적 세포를 분석하기 위한 방법 |
| AU2020312163A1 (en) * | 2019-07-05 | 2022-02-17 | Intellexon Gmbh | HLA-H in medicine and diagnostics |
| CN110491450B (zh) * | 2019-08-23 | 2023-05-16 | 深圳市新合生物医疗科技有限公司 | 肿瘤新生抗原预测平台及其应用 |
| JP2022553073A (ja) * | 2019-10-25 | 2022-12-21 | インテレクソン ゲゼルシャフト ミット ベシュレンクテル ハフツング | 治療・診断標的としてのｈｌａ－ｈ， ｈｌａ－ｊおよびｈｌａ－ｌ |
| CA3183756A1 (en) * | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
| US10981997B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US10981996B1 (en) | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US11976120B2 (en) | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| KR20230015996A (ko) * | 2020-06-30 | 2023-01-31 | 하버 바이오메드 (상하이) 컴퍼니 리미티드 | H2l2 및 hcab 구조를 갖는 결합 단백질 |
| WO2022060893A1 (en) * | 2020-09-15 | 2022-03-24 | Duke University | Antibodies that target hla-e-host peptide complexes and uses thereof |
| EP4388012A4 (en) * | 2021-08-20 | 2025-09-17 | Univ Duke | ANTIBODIES TARGETING HLA-E-HOST PEPTIDE COMPLEXES AND THEIR USES |
| JPWO2023112965A1 (cg-RX-API-DMAC7.html) * | 2021-12-15 | 2023-06-22 | ||
| KR20250099771A (ko) * | 2022-10-05 | 2025-07-02 | 티스캔 테라퓨틱스, 인크. | Magea1 면역원성 펩타이드, magea1 면역원성 펩타이드를 인식하는 결합 단백질 및 이의 용도 |
| WO2024084091A1 (en) * | 2022-10-21 | 2024-04-25 | Medizinische Universität Wien | Materials and methods to treat epstein-barr virus (ebv) and ebv-induced diseases |
| TW202513802A (zh) * | 2023-09-22 | 2025-04-01 | 美商再生元醫藥公司 | 獲得與多肽－ｍｈｃ界面結合的抗體分子之方法 |
| GB202316281D0 (en) * | 2023-10-24 | 2023-12-06 | Replay Holdings Inc | Methods and compositions for modulating immune cell activity in cellular therapy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE200679T1 (de) * | 1997-04-14 | 2001-05-15 | Micromet Ag | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen |
| EP1019439B1 (en) * | 1997-10-02 | 2011-11-16 | Altor BioScience Corporation | Soluble single-chain t-cell receptor proteins |
| GB9725764D0 (en) * | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| NZ521715A (en) * | 2000-04-28 | 2008-01-31 | Mannkind Corp | Method of identifying and producing antigen peptides and use thereof as vaccines |
| JP2010519256A (ja) * | 2007-02-23 | 2010-06-03 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 免疫疾患を治療するために、ＨＬＡ−Ｅ／Ｑａ−１拘束性ＣＤ８＋Ｔ細胞制御性経路を活性化または遮断する方法 |
| WO2008120202A2 (en) * | 2007-03-29 | 2008-10-09 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
| GB201003198D0 (en) * | 2010-02-25 | 2010-04-14 | Arab Biotechnology Company | Compositions and methods for the treatment of cancer |
| BR112013002532A2 (pt) * | 2010-08-05 | 2016-05-31 | Hoffmann La Roche | proteína de fusão de citocina anti-viral do anticorpo anti-mhc |
| WO2013075105A2 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Tcl1 peptides for immunotherapy |
| US10656156B2 (en) * | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
| TWI853985B (zh) * | 2013-12-04 | 2024-09-01 | 日商中外製藥股份有限公司 | 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫 |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| NL2014935B1 (en) * | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| RU2018102526A (ru) * | 2015-06-24 | 2019-07-25 | Еурека Терапьютикс, Инк. | Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение |
| MA45491A (fr) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
-
2018
- 2018-01-24 CN CN201880020694.1A patent/CN110809580A/zh active Pending
- 2018-01-24 EP EP18745174.5A patent/EP3573997A4/en not_active Withdrawn
- 2018-01-24 JP JP2019560066A patent/JP7303750B2/ja active Active
- 2018-01-24 WO PCT/US2018/015086 patent/WO2018140525A1/en not_active Ceased
- 2018-08-14 US US16/103,764 patent/US20190071502A1/en not_active Abandoned
-
2023
- 2023-06-22 JP JP2023102868A patent/JP2023134503A/ja active Pending